ATYR — aTYR PHARMA INC
—
Nasdaq ·
Health Care ·
Biotechnology ·
CIK 1339970 ·
Last close
$0.49
Market Cap
$47.65M
52W High
$1.05
52W Low
$0.40
ADV30
1,899,450
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 0 | — | -11,436,000 | -10,791,000 | 79,654,000 | 10,008,000 | 21,913,000 |
| Dec 2025 | 0 | — | -14,796,000 | -13,963,000 | 93,003,000 | 10,743,000 | 25,715,000 |
| Sep 2025 | 190,000 | — | -26,745,000 | -25,744,000 | 106,652,000 | 6,150,000 | 26,608,000 |
| Jun 2025 | 0 | — | -20,313,000 | -19,531,000 | 101,534,000 | 17,220,000 | 26,878,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-59,083,000
Investing CF
$10,861,000
Financing CF
$47,241,000
CapEx
$-231,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-0.73
As of
2026-06-07
Balance + Analyst (yfinance extras)
Retained Earnings
$-616,955,000
Inventory
—
Receivables
$477,000
ST Investments
$56,505,000
EBIT TTM
$-73,290,000
Pretax Income TTM
$-70,034,000
Interest Exp TTM
—
Analysts
7
Yahoo Snapshot (yfinance, live)
Total Revenue
$190,000
EBITDA
$-72,631,000
Free Cash Flow
$-32,652,250
Enterprise Value
$-7,382,526
Total Cash
$66,513,000
Total Debt
$11,700,000
Shares Out
98,051,212
Trailing EPS
$-0.74
Book Value
$0.59
ROE
-105.6%
ROA
-51.8%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 190,000 | -77,627,000 | -74,118,000 | 93,003,000 | 25,715,000 | — | -61,986,000 |
| Dec 2024 | 235,000 | -67,914,000 | -64,023,000 | 96,830,000 | 26,998,000 | — | -69,119,000 |
| Dec 2023 | 353,000 | -54,919,000 | -50,389,000 | 120,653,000 | 30,183,000 | — | -33,221,000 |
| Dec 2022 | 10,386,000 | -46,404,000 | -45,338,000 | 95,786,000 | 24,502,000 | — | -41,886,000 |
TTM Snapshot
Revenues TTM
$0
NetIncome TTM
$-16,306,000
OpCashFlow TTM
$0
Assets (Latest)
$96,830,000
Forward EPS
$-0.63
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| TIL | Instil Bio, Inc. | $48.29M | $7.12 | — |
| SCLX | Scilex Holding Co | $46.87M | $6.66 | — |
| INMB | Inmune Bio, Inc. | $46.52M | $1.75 | — |
| BKHA | Black Hawk Acquisition Corp | $48.93M | $11.78 | — |
| TCRX | TScan Therapeutics, Inc. | $45.38M | $0.74 | — |
News headlines (Yahoo Finance, 1h cache)
aTyr Pharma to Present Subgroup Analysis of Phase 3 EFZO-FIT™ Study of Efzofitimod in Pulmonary Sarcoidosis at WASOG 2026
2026-07-15 12:00 · Yahoo
What It Means To Hold Moderna Stock In A Crash
2026-07-13 13:12 · Yahoo
Life Sciences Virtual Investor Forum Presentations Now Available for On-Demand Viewing
2026-06-26 12:35 · Yahoo
Life Sciences Virtual Investor Forum Agenda Announced for June 24th & 25th
2026-06-23 12:35 · Yahoo
aTyr Pharma Announces First Quarter 2026 Results and Provides Corporate Update
2026-05-15 12:00 · Yahoo
aTyr Pharma to Participate in Upcoming Investor Conferences
2026-05-13 20:01 · Yahoo
aTyr Pharma Revamps Efzofitimod Path With New Phase III Sarcoidosis Trial
2026-05-12 00:09 · Yahoo
aTyr Pharma Provides Regulatory and Clinical Update for Efzofitimod in Pulmonary Sarcoidosis Following FDA Type C Meeting
2026-05-11 20:01 · Yahoo
Interstitial Lung Disease Market to Witness Accelerated Growth at a CAGR of 8.7% During the Forecast Period (2026–2036) Due to the Launch of Emerging Therapies | DelveInsight
2026-04-08 17:00 · Yahoo
aTyr Pharma Spotlights Efzofitimod Phase 3 Learnings, Eyes Mid-April FDA Type C Meeting
2026-03-12 12:03 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.